Literature DB >> 19259311

Toward personalized, targeted therapy of gastrointestinal stromal tumor.

Jonathan C Trent1.   

Abstract

Entities:  

Year:  2008        PMID： 19259311      PMCID： PMC2632559     

Source DB:  PubMed          Journal:  Gastrointest Cancer Res        ISSN： 1934-7820


× No keyword cloud information.
  9 in total

1.  KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.

Authors:  Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
Journal:  Eur J Cancer       Date:  2006-04-18       Impact factor: 9.162

2.  Unlucky number 13? Differential effects of KIT exon 13 mutation in gastrointestinal stromal tumors.

Authors:  John C McAuliffe; Wei-Lein Wang; Giovanni M Pavan; Sabrina Pricl; Dan Yang; Su S Chen; Alexander J F Lazar; Raphael E Pollock; Jonathan C Trent
Journal:  Mol Oncol       Date:  2008-05-10       Impact factor: 6.603

3.  Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.

Authors:  Samuel Singer; Brian P Rubin; Marcia L Lux; Chang-Jie Chen; George D Demetri; Christopher D M Fletcher; Jonathan A Fletcher
Journal:  J Clin Oncol       Date:  2002-09-15       Impact factor: 44.544

4.  Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.

Authors:  Jaap Verweij; Paolo G Casali; John Zalcberg; Axel LeCesne; Peter Reichardt; Jean-Yves Blay; Rolf Issels; Allan van Oosterom; Pancras C W Hogendoorn; Martine Van Glabbeke; Rossella Bertulli; Ian Judson
Journal:  Lancet       Date:  2004 Sep 25-Oct 1       Impact factor: 79.321

5.  Association of intratumoral vascular endothelial growth factor expression and clinical outcome for patients with gastrointestinal stromal tumors treated with imatinib mesylate.

Authors:  John C McAuliffe; Alexander J F Lazar; Dan Yang; Dejka M Steinert; Wei Qiao; Peter F Thall; A Kevin Raymond; Robert S Benjamin; Jonathan C Trent
Journal:  Clin Cancer Res       Date:  2007-11-15       Impact factor: 12.531

6.  Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.

Authors:  Charles D Blanke; Cathryn Rankin; George D Demetri; Christopher W Ryan; Margaret von Mehren; Robert S Benjamin; A Kevin Raymond; Vivien H C Bramwell; Laurence H Baker; Robert G Maki; Michael Tanaka; J Randolph Hecht; Michael C Heinrich; Christopher D M Fletcher; John J Crowley; Ernest C Borden
Journal:  J Clin Oncol       Date:  2008-02-01       Impact factor: 44.544

7.  Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.

Authors:  M Debiec-Rychter; H Dumez; I Judson; B Wasag; J Verweij; M Brown; S Dimitrijevic; R Sciot; M Stul; H Vranck; M Scurr; A Hagemeijer; M van Glabbeke; A T van Oosterom
Journal:  Eur J Cancer       Date:  2004-03       Impact factor: 9.162

8.  Optimizing imatinib mesylate treatment in gastrointestinal stromal tumors.

Authors:  Yixing Jiang; Lee Ming; Alberto J Montero; Eric Kimchi; Mehrdad Nikfarjam; Kevin F Staveley-O'Carroll
Journal:  Gastrointest Cancer Res       Date:  2008-09

9.  Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability.

Authors:  N Widmer; L A Decosterd; S Leyvraz; M A Duchosal; A Rosselet; M Debiec-Rychter; C Csajka; J Biollaz; T Buclin
Journal:  Br J Cancer       Date:  2008-05-06       Impact factor: 7.640
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.